ATLANTA, Jan. 13, 2014 /PRNewswire/ -- EndoChoice® has added two highly regarded business leaders to the board of directors. Mr. Scott Davis, the Chairman and CEO of UPS (NYSE: UPS) and Mr. Scott Huennekens, President and CEO of Volcano Corporation (NASDAQ: VOLC) have joined the board as EndoChoice looks to more than double its revenue in 2014.
"I have been watching EndoChoice grow for the last several years," said Davis. "The emphasis on innovation, quality execution and growth has helped EndoChoice become one of the most dynamic players in the medical technology industry. The future for EndoChoice is very bright."
UPS and EndoChoice have been working together to deliver EndoChoice's proprietary products and services to hospitals, ambulatory surgery centers and physician offices around the world.
"You can count on one hand the number of medtech companies over $50 million that are growing more than 30% in 2014. There is only one with which I'm familiar that is going to grow at greater than 100%," said Huennekens. "Opportunities to help guide companies on this growth trajectory are rare; I'm excited to be involved with EndoChoice."
EndoChoice is the fastest growing company in the video endoscopy market with the launch of the Fuse™ Full Spectrum Endoscopy™ system, the first and only endoscope with multiple imagers providing endoscopists the potential to diagnose and treat more diseases of the gastrointestinal tract.
Based in Atlanta, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopes. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com
EndoChoice® and Fuse™ are trademarks of EndoChoice®, Inc.
For more information, press only: Doug Ladd, Chief Marketing Officer 513-608-6873 or Doug.Ladd@endochoice.com